Search company, investor...

Allos Therapeutics

allos.com

Founded Year

1992

Stage

Acq - P2P | Acquired

Total Raised

$66.61M

Valuation

$0000 

Revenue

$0000 

About Allos Therapeutics

Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company's lead product candidate, pralatrexate (PDX) is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pralatrexate in patients with non-small cell lung cancer, bladder cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkins lymphoma (NHL). Allos currently retains exclusive worldwide rights to pralatrexate and RH1 for all indications. In September 2012, Allos Therapeutics was acquired by Spectrum Pharmaceuticals. The valuation of Allos Therapeutics was undisclosed. Other terms of the deal were not released.

Headquarters Location

11080 Circlepoint Road Suite 200

Westminster, Colorado, 80020,

United States

303-426-6262

Missing: Allos Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Allos Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Allos Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Allos Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Allos Therapeutics Patents

Allos Therapeutics has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/17/2013

2/27/2018

Experimental cancer drugs, Lung cancer, Monoclonal antibodies, Monoclonal antibodies for tumors, Fluoroarenes

Grant

Application Date

7/17/2013

Grant Date

2/27/2018

Title

Related Topics

Experimental cancer drugs, Lung cancer, Monoclonal antibodies, Monoclonal antibodies for tumors, Fluoroarenes

Status

Grant

Latest Allos Therapeutics News

Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Jul 21, 2012

googlecse  Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics Charles Gross , Benzinga Staff Writer   {{following ? "Following" : "Follow"}} July 20, 2012 6:41pm   Comments Share: Spectrum Pharmaceuticals (NASDAQ: SPPI ) and Allos Therapeutics (NASDAQ: ALTH ) announced Friday that Spectrum has provided an additional extension of the offer period in connection with its tender offer to purchase all of the outstanding shares of common stock of Allos for $1.82 per share in cash, without interest and less any applicable withholding taxes. The extension was made in order for Spectrum and Allos to continue cooperating with the Federal Trade Commission in relation to the previously announced Request for Additional Information and Documentary Material that each party received on May 9, 2012 from the FTC under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to the acquisition of Allos by Spectrum. The offer, which was previously scheduled to expire at 5:00 p.m., Eastern time, on Monday, July 23, 2012, has been extended until 5:00 p.m., Eastern time, on Monday, August 6, 2012, unless extended for an additional period. All terms and conditions of the tender offer shall remain unchanged during the extended period. The depositary for the tender offer has advised Spectrum that, as of 5:00 p.m., Eastern time, on July 20, 2012, a total of approximately 65,241,335 shares of Allos common stock, representing approximately 61.0% of the outstanding shares of Allos common stock, were validly tendered and not withdrawn. © 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Allos Therapeutics Frequently Asked Questions (FAQ)

  • When was Allos Therapeutics founded?

    Allos Therapeutics was founded in 1992.

  • Where is Allos Therapeutics's headquarters?

    Allos Therapeutics's headquarters is located at 11080 Circlepoint Road, Westminster.

  • What is Allos Therapeutics's latest funding round?

    Allos Therapeutics's latest funding round is Acq - P2P.

  • How much did Allos Therapeutics raise?

    Allos Therapeutics raised a total of $66.61M.

  • Who are the investors of Allos Therapeutics?

    Investors of Allos Therapeutics include Spectrum Pharmaceuticals, Warburg Pincus, FrontPoint Partners, Deephaven Capital Management, Heights Capital Management and 22 more.

  • Who are Allos Therapeutics's competitors?

    Competitors of Allos Therapeutics include Lipella Pharmaceuticals, Sierra Oncology, Array Biopharma, Orexigen Therapeutics, Biosceptre International and 13 more.

Compare Allos Therapeutics to Competitors

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

A
Adriacell

Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.

P
Pique Therapeutics

Pique Therapeutics is a biotechnology company focused initially on the treatment of cancer. Pique's lead product is a therapeutic vaccine for non-small cell lung cancer in Phase 2 clinical trials. Pique is also utilizing its therapeutic vaccine technology in additional areas of oncology, with products in pre-clinical stage for pancreatic, colorectal, and head and neck cancers.

S
Serentis

Serentis is a biopharmaceutical company which aims to develop a pipeline of products to address unmet medical needs in the dermatology field. The company's strategy is to establish a clinical stage development pipeline by the reprofiling of existing drugs and through the licensing or acquisition of projects from external sources. This is an approach that Serentis' management team has successfully pursued in the past.

O
Orabio

Founded in 2005 Ora Bio Ltd, a biopharmaceutical company, is engaged in the repositioning of existing drugs for second-use applications. nnThe Company is developing its two products, the ORA101 and ORA102, as drugs for non-small cell lung cancer (NSCLC) and age-related macular degeneration (AMD) respectively. Both the company's products are currently in Phase II clinical trials.n

E
Escientia

is a contract research organization that collaborates with R&D departments of biotechnology and biopharmaceutical companies to discover and develop new medicines. The company also engages in its own drug discovery agenda to develop treatments of treat tropical diseases such as malaria.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.